Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study (CROSBI ID 275837)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Madir, Anita ; Božin, Tonći ; Mikolašević, Ivana ; Milić, Sandra ; Štimac, Davor ; Mijić, Maja ; Filipec Kanižaj, Tajana ; Biloglav, Zrinka ; Lucijanić, Marko ; Lucijanić, Iva et al. Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study // Croatian medical journal, 60 (2019), 6; 494-502. doi: 10.3325/cmj.2019.60.494

Podaci o odgovornosti

Madir, Anita ; Božin, Tonći ; Mikolašević, Ivana ; Milić, Sandra ; Štimac, Davor ; Mijić, Maja ; Filipec Kanižaj, Tajana ; Biloglav, Zrinka ; Lucijanić, Marko ; Lucijanić, Iva ; Grgurević, Ivica

engleski

Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study

Aim To assess the measures of disease frequency and determine the clinical features of primary biliary cholangitis (PBC) in two Croatian regions. Methods Databases of two tertiary hospitals, one located in the continental and one in the coastal region of Croatia, were retrospectively searched for PBC patients diagnosed from 2007 to 2018. Epidemiologic data analysis was restricted to patients from each hospital's catchment area. We analyzed factors related to response to therapy and event-free survival (EFS), defined as absence of ascites, variceal bleeding, encephalopathy, hepatocellular carcinoma, liver transplantation (LT), or death. In addition, we determined clinical and demographic data of transplanted PBC patients. Results Out of 83 PBC patients, 86.7% were female, with a median age at diagnosis of 55 years. Average PBC incidence for the 11-year period was 0.79 and 0.89 per 100 000 population, whereas the point prevalence on December 31, 2017 was 11.5 and 12.5 in the continental and coastal region, respectively. Of 76 patients with complete medical records, 21% had an advanced disease stage, 31.6% had an associated autoimmune condition, and all received ursodeoxycholic acid. EFS rate at 5 years was 95.8%. In an age and sex- adjusted multivariate Cox regression model, the only factor significantly associated with inferior EFS was no response to therapy (HR = 18.4 ; P=0.018). Of all Croatian patients who underwent LT, 3.8% had PBC, with the survival rate at 5 years after LT of 93.4%. Conclusion This study gives pioneer insights into the epidemiological and clinical data on PBC in Croatia, thus complementing the PBC map of Southeast Europe.

ursodeoxycholic acid ; biochemical response ; survival analysis ; cirrhosis ; cholestasis ; progression ; prevalence ; recurrence ; prognosis ; disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

60 (6)

2019.

494-502

objavljeno

0353-9504

10.3325/cmj.2019.60.494

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost